Condensed Interim Consolidated Financial Statements

(unaudited)

Oncolytics Biotech® Inc.

Oncolytics Biotech Inc. was incorporated on April 2, 1998, under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. On April 8, 1998, we changed our name to Oncolytics Biotech Inc. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Market (the "Nasdaq"). Our principal place of business is located at 804, 322 11th Avenue S.W., Calgary, Alberta, Canada.

We are a clinical-stage biopharmaceutical company developing pelareorep, a well-tolerated intravenously delivered

immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. Our primary focus is to position pelareorep as a platform immunotherapy for the treatment of gastrointestinal (GI) tumors and advance our GI program to registration-enabled clinical studies. We are exploring opportunities for registrational programs and investigator-sponsored trials in metastatic pancreatic cancer, second-line or later anal cancer, and metastatic colorectal cancer.

We have not been profitable since our inception and expect to continue to incur substantial losses as we continue our research and development efforts. As at September 30, 2025, we had an accumulated deficit of $504,965. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. To date, we have funded our operations mainly through issuing additional capital via public offerings, equity distribution arrangements, and the exercise of warrants and stock options.

Management assesses our ability to continue as a going concern when preparing our condensed interim consolidated financial statements. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but not limited to, twelve months from the end of the reporting period. As at September 30, 2025, we had cash and cash equivalents of $12,352. We estimate we can currently fund our operations into March 2026. Factors that will affect our anticipated cash needs for the next twelve months include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken.

Our ability to continue as a going concern is dependent upon raising additional financing through equity or strategic collaborations and transactions. We plan on raising additional funds through the sale of our common shares or other capital resources, such as strategic collaborations and debt, to fund our ongoing operations. However, given the difficulty for micro-cap market capitalization companies to raise significant capital, there can be no assurance that additional liquidity will be available under acceptable terms or at all. Furthermore, if we are unable to obtain additional financing when required, there can be no assurance that we will be able to sufficiently reduce or eliminate our planned expenditures to extend our operating runway. These material uncertainties raise substantial doubt on our ability to continue as a going concern and meet our obligations as they come due and, accordingly, the appropriateness of the use of accounting principles applicable to a going concern.

These condensed interim consolidated financial statements were prepared in accordance with International Financial Reporting Standards ("IFRS") applicable to a going concern. However, the use of the going concern assumption on which these condensed interim consolidated financial statements are prepared may not be appropriate based on the factors described above.

These condensed interim consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and statements of financial position classifications that would be necessary if we were unable to realize our assets and settle our liabilities as a going concern in the normal course of operations. Such adjustments could be material.

These condensed interim consolidated financial statements have been prepared in accordance with IFRS and in compliance with International Accounting Standard ("IAS") 34 Interim Financial Reporting as issued by the International Accounting Standards Board ("IASB").

Our condensed interim consolidated financial statements for the three and nine months ended September 30, 2025, were authorized for issue in accordance with a resolution of the Board of Directors on November 12, 2025.

These condensed interim consolidated financial statements have been prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.

The notes presented in these condensed interim consolidated financial statements include only significant events and transactions occurring since our last fiscal year end and are not fully inclusive of all matters required to be disclosed in our annual audited consolidated financial statements. Accordingly, these condensed interim consolidated financial statements should be read in conjunction with our most recent annual audited consolidated financial statements for the year ended December 31, 2024.

Our condensed interim consolidated financial statements include our financial statements and the financial statements of our subsidiaries, Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (U.S.) Inc., and are presented in Canadian dollars, our functional currency.

The preparation of our condensed interim consolidated financial statements in conformity with IFRS requires us to make judgments, estimates, and assumptions that affect the application of accounting policies, the reported amounts, and disclosures in our condensed interim consolidated financial statements and accompanying notes. Management makes estimates based on our best knowledge of current events and actions that the Company may undertake in the future. We consider the potential impact of certain external factors outside of our control, including global political conflicts, supply chain disruptions, inflation, fluctuating interest rates, and liquidity, when making certain estimates and judgments relating to the preparation of these condensed interim consolidated financial statements. Estimates and underlying assumptions are reviewed on an ongoing basis. Actual results could differ from these estimates, and such differences could be material.

The accounting policies applied in these condensed interim consolidated financial statements are the same as those applied in our audited consolidated financial statements for the year ended December 31, 2024.

In April 2024, the IASB issued IFRS 18 Presentation and Disclosure in Financial Statements which replaces IAS 1 Presentation of Financial Statements. IFRS 18 introduces new requirements on presentation within the statement of profit or loss, including specified totals and subtotals. It also requires disclosure of management-defined performance measures and includes new requirements for aggregation and disaggregation of financial information based on the identified roles of the primary financial statements and the notes. Narrow scope amendments have been made to IAS 7 Statement of Cash Flows and some requirements previously included within IAS 1 have been moved to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors, which has also been renamed IAS 8 Basis of Preparation of Financial Statements. IAS 34 Interim Financial Reporting has also been amended to require disclosure of management-defined performance measures. IFRS 18 and the amendments to the other standards are effective for annual periods beginning on or after January 1, 2027, with early

application permitted. IFRS 18 applies retrospectively to both annual and interim financial statements. We do not expect this amendment to materially impact our consolidated financial statements.

Cash equivalents consist of interest-bearing deposits with our bank totaling $9,804 as at September 30, 2025 (December 31, 2024 – $12,312).  

In 2023, we were selected by the Pancreatic Cancer Action Network (PanCAN) as the recipient of its Therapeutic Accelerator Award to conduct a clinical trial with pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor in pancreatic cancer patients. Under the terms of the award agreement, we are entitled to receive up to US$5 million in funding for eligible research expenses, and we must comply with the conditions set out with the award agreement, including providing periodic performance progress reports. As at September 30, 2025, we recorded US$122 ($170) (December 31, 2024 – US$1,125 ($1,618)) in other liabilities representing unapplied funding received from PanCAN.

We have office space leases with initial lease terms generally between 3 to 6 years. We currently do not have leases with residual value guarantees or leases not yet commenced to which we are committed. We have variable lease payments related to office space lease operating costs that are not material. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate, as rates implicit in the leases were not readily determinable. The weighted average rate applied was 15%.

Our total undiscounted lease liabilities as at September 30, 2025, were as follows:

Our common share purchase warrants ("warrants") with a U.S. dollar exercise price, which differs from our functional currency, are treated as a derivative measured at fair value, and revalued each period end at fair value through profit and loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised.

Changes in the value of our warrant derivative were as follows:

The following table summarizes our outstanding warrant derivative as at September 30, 2025:

On August 8, 2023, pursuant to an underwritten public offering, we issued 6,667,000 units for gross proceeds of $20,185 (US$15,001) at a price of US$2.25 per unit. On September 7, 2023, pursuant to the over-allotment option exercised by the underwriter, we issued an additional 1,000,050 units for gross proceeds of $3,077 (US$2,250) at a price of US$2.25 per unit. Each unit consisted of one common share and one common share purchase warrant ("warrant"), which were immediately separable and issued separately in this offering. Each warrant entitles the holder to purchase one common share at an exercise price of US$2.81 up to 60 months from the date of issuance. Proceeds were allocated amongst common shares and warrants by applying a relative fair value approach, which resulted in $17,724 recorded in share capital and an initial warrant derivative liability of $7,360. The difference between the fair value of the warrants and their allocated proceeds was a discount of $1,822, which is amortized on a straight-line basis over the five-year expected life of the warrants and recorded under change in fair value of warrant derivative on our consolidated statement of loss and comprehensive loss.

We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on the U.S. Department of Treasury benchmark treasury yield rates with an approximate equivalent remaining term in effect at the time of valuation, and the expected life represents the estimated length of time the warrants are expected to remain outstanding.

The estimated fair value of the warrant derivative was determined using the following assumptions:

Unlimited number of no par value common shares

(a)On June 17, 2022, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$65,000 over a 25-month period through the facilities of the Nasdaq in the United States. This sales agreement was terminated on July 17, 2024. During the nine months ended September 30, 2024, we sold 2,560,933 common shares for gross proceeds of $4,016 (US$2,964) at an average price of $1.57 (US$1.16). We received proceeds of $3,895 (US$2,875) after commissions of $121 (US$89). In total, we incurred share issue costs (including commissions) of $207.

(b)On August 2, 2024, we entered into an ATM equity distribution agreement with Cantor Fitzgerald & Co. (Cantor). The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$50,000 over a 25-month period through the facilities of the Nasdaq in the United States. This sales agreement was terminated on August 22, 2025, following our voluntary delisting from the Toronto Stock Exchange (TSX). During the nine months ended September 30, 2025, we sold 12,441,368 (September 30, 2024 - 35,600) common shares for gross proceeds of $13,147 (US$9,392) (September 30, 2024 - $46 (US$34)) at an average price of $1.06 (US$0.75) (September 30, 2024 - $1.29 (US$0.96)). We received proceeds of $12,753 (US$9,110) (September 30, 2024 - $45 (US$33) after commissions of $394 (US$282) (September 30, 2024 - $1 (US$1)). In total, we incurred share issue costs (including commissions) of $522 (September 30, 2024 - $375).

(c)On April 10, 2025, we entered into a share purchase agreement with Alumni Capital LP (Alumni), an institutional investor. Under the terms of the agreement, we had the right to sell, and Alumni had the obligation to purchase up to US$20 million worth of common shares over a 15-month period based on the market price at the time of each sale to Alumni. The agreement limited Alumni's beneficial ownership to 4.99% of our common shares outstanding immediately prior to each sale, which can be increased to 9.99% upon mutual agreement. The agreement also limited our sale of common shares to 19.99% of our total outstanding common shares as at the date that the share purchase agreement was entered into, unless and until we have obtained shareholder approval under applicable Nasdaq rules. Subject to the terms of the agreement, we had sole discretion over the timing and amount of all common share sales. We issued an initial commitment fee of 816,326 common shares at the execution of the agreement. An additional 816,326 common shares would be issued on a pro rata basis upon the delivery of purchase notices as an additional commitment fee. This share purchase agreement was terminated on August 22, 2025, following our voluntary delisting from the TSX.

During the nine months ended September 30, 2025, we sold 6,650,000 common shares for gross proceeds of $3,233 (US$2,348) at an average price of $0.49 (US$0.35). We also issued 816,326 initial commitment and 95,826 additional commitment shares fair valued at $608 (US$435). In total, we incurred share issue costs (including the initial commitment and additional commitment fees) of $759.

(d)During the nine months ended September 30, 2025, we issued 1,951,699 shares to consultants as partial or total consideration for services received (see note 8).

Our share-based compensation expense was as follows:

Our amended and restated Stock Option Plan and Share Award Plan (collectively, the "Equity Incentive Plans") were approved by our shareholders at the annual general meeting of shareholders on May 9, 2023. Pursuant to our Equity Incentive Plans, we may grant stock options, restricted share unit awards ("RSA"), and performance share unit awards ("PSA"). The number of common shares reserved for issuance under our Equity Incentive Plans in aggregate shall not exceed 14% of the total number of issued and outstanding common shares from time to time. As at September 30, 2025, there were 2,591,448 common shares available for grant under the Equity Incentive Plans.

In June 2025, we granted inducement equity awards to our new Chief Executive Officer ("New CEO") and Chief Business Officer ("CBO"). These awards included stock options and performance-based stock options ("Inducement Stock Options") and performance restricted share unit awards ("Inducement Share Awards"). The grants were made as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4), and therefore did not require shareholder approval.

(a)Our stock option activity related to the Equity Incentive Plan and Inducement Stock Options for the nine months ended September 30 was as follows:

The following table summarizes information about the stock options outstanding and exercisable at September 30, 2025:

Our option grants vest either immediately or annually over periods ranging from one to three years, except for our performance-based option grant, which vests upon achieving certain financing objectives during the service period.

We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on observed interest rates appropriate for the expected term of the grants. The expected life of the options represents the estimated length of time the options are expected to remain outstanding.

The estimated fair value of the stock options granted during the nine months ended September 30 was determined using the following weighted average assumptions:

(b)Our share unit award activity related to the Equity Incentive Plan and Inducement Share Awards for the nine months ended September 30 was as follows:

(1)The weighted average fair value of the RSAs granted was $0.76 in 2025.

During the nine months ended September 30, 2025, we granted RSAs to our independent members of the Board of Directors, our Interim Chief Executive Officer ("Interim CEO), our Former Chief Executive Officer ("Former CEO"), and a consultant for services provided.

The RSAs granted to our independent Board of Directors were in lieu of their cash compensation for the first half of 2025. These RSAs and those granted to the Former CEO vested immediately upon grant. RSAs granted to our Interim CEO were subject to immediate vesting or cliff vesting in two years, depending on the terms of the individual award.

The Inducement Share Awards granted to our New CEO and CBO will vest upon our entry into a definitive agreement involving either (i) the acquisition of our company or (ii) the exclusive license of pelareorep. Upon such triggering event, our New CEO will be entitled to receive a number of common shares equal to 2% of our then-outstanding common shares, and our CBO will be entitled to receive 500,000 common shares.

During the nine months ended September 30, 2025, we issued 1,951,699 shares to consultants as partial or total consideration for services received. We measured and recognized the fair value of the services received in the nine months ended September 30, 2025, based on either the market price of the services pursuant to the consulting agreement or the price of the Company's common shares over the service period (the weighted average fair value of the shares issued was US$1.19).

In consideration of the services rendered by the underwriter as part of a public offering in 2023, we issued 536,693 compensation warrants. Each compensation warrant is exercisable into one common share at an exercise price of US$2.25 up to 60 months from the date of issuance. At issuance date, we used the Black-Scholes valuation model to estimate the fair value of the services rendered. As at September 30, 2025, and September 30, 2024, there were 536,693 compensation warrants outstanding.

 

Loss per common share is calculated by dividing net loss for the period and the weighted average number of common shares outstanding for the three and nine months ended September 30, 2025, of 101,315,089 and 92,376,486, respectively (September 30, 2024 - 77,016,848 and 76,120,580, respectively). The effect of any potential exercise of our stock options, share unit awards, and warrants outstanding during the period has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.

 

We are committed to payments of approximately $3,200 for activities mainly related to our clinical trial and manufacturing programs, which are expected to occur over the next two years. We are able to cancel most of these agreements with notice.

 

Our objective when managing capital is to maintain adequate cash resources to support planned activities, including our clinical trial program, product manufacturing, administrative costs, and intellectual property expansion and protection. See note 1 for the discussion on our ability to continue as a going concern. We include shareholders' equity and cash and cash equivalents in the definition of capital.

We have no debt other than accounts payable and accrued liabilities and lease liabilities. We also have commitments relating to completing our research and development of pelareorep.

In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the associated costs. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year’s activity. Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.

Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that are converted to common shares upon exercise. Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital. There are no assurances that funds will be made available to us when required.

 

As at September 30, 2025, and December 31, 2024, the carrying amount of our cash and cash equivalents, other receivables, accounts payable and accrued liabilities, and other liabilities approximated their fair value due to their short-term maturity. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and, therefore, do not trade on an active market. As at September 30, 2025, the fair value of our warrant derivative was $29 (December 31, 2024 - presented as an asset of $980) (see note 6).

Credit risk is the risk of a financial loss if a counterparty to a financial instrument fails to meet its contractual obligations. As at September 30, 2025, we were exposed to credit risk on our cash and cash equivalents in the event of non-performance by

counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents.

Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. For the nine months ended September 30, 2025, we were primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar and Euro, as a portion of our financial assets and liabilities were denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have increased our comprehensive loss in 2025 by approximately $89 (September 30, 2024 - decreased $29). The impact of a $0.01 increase in the value of the Euro against the Canadian dollar would have increased our comprehensive loss in 2025 by approximately $36 (September 30, 2024 - $25).

Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. See note 1 for the discussion on our ability to continue as a going concern. We manage liquidity risk by managing our capital structure as outlined in note 11. Accounts payable and accrued liabilities are all due within the current operating period. Other liabilities associated with funding received from PanCAN (see note 4) are expected to be applied within the current operating period. See note 5 for a maturity analysis of our lease liabilities.

 

Our research and development personnel-related expenses included employee compensation and benefits of $1,411 and $4,231 for the three and nine months ended September 30, 2025, respectively (September 30, 2024 - $1,210 and $3,734, respectively).

Our general and administrative personnel-related expenses included employee compensation and benefits of $645 and $2,292 for the three and nine months ended September 30, 2025, respectively (September 30, 2024 - $680 and $1,802, respectively).

Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel comprise the Board of Directors, Executive Officers, President, and Vice Presidents.

On October 17, 2025, we entered into an ATM sales agreement with BTIG, LLC. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$50,000 through the facilities of the Nasdaq in the United States.

This discussion and analysis should be read in conjunction with our unaudited condensed interim consolidated financial statements and notes thereto as at and for the three and nine months ended September 30, 2025, and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") contained in our annual report for the year ended December 31, 2024. The financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). Unless otherwise indicated, all references to "$" and "dollars" in this discussion and analysis mean thousands of Canadian dollars.

All references in this MD&A to "the Company," "Oncolytics," "we," "us," or "our" and similar expressions refer to Oncolytics Biotech Inc. and the subsidiaries through which it conducts its business unless otherwise indicated.

The following discussion contains forward-looking statements, within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements, including:

•our belief as to the potential and mechanism of action of pelareorep, an intravenously delivered immunotherapeutic agent, as a cancer therapeutic;

•our business strategy, goals, focus, and objectives for the development of pelareorep, including our primary focus on positioning pelareorep as a platform immunotherapy for the treatment of gastrointestinal tumors and advance our GI program to registration-enabled clinical studies, and our exploration of opportunities for registrational programs and investigator-sponsored trials in metastatic pancreatic cancer, second-line or later anal cancer, and metastatic colorectal cancer;

•our expectation that we will obtain regulatory clarity on a registration-enabled study for first-line mPDAC by the end of 2025;

•our expectations regarding the ongoing U.S. federal government shutdown, and its impacts on the timing of the Special Meeting of Shareholders and implementation of the Domestication;

•our expectation to provide a Cohort 5 interim efficacy update on our GOBLET study and discuss plans for a single-arm accelerated approval study for Cohort 4 with the FDA in the first quarter of 2026, and our plans to expand the GOBLET study to U.S. sites starting in the fourth quarter of 2025;

•our expectations regarding the size, composition, and expertise of the SAB;

•our expectation that pelareorep’s ability to enhance innate and adaptive immune responses within the tumor microenvironment will play an increasingly important role as our clinical development program advances, and our belief that this approach increases opportunities for expanding our clinical program and business development and partnering opportunities, has the most promise for generating clinically impactful data and offers the most expeditious path to regulatory approval;

•our belief that by priming the immune system with pelareorep, we can increase the proportion of patients who respond to various cancer treatments, including immunotherapies, especially in cancers where existing treatment regimens have failed or provided limited benefit;

•our expectation that we will incur substantial losses and will not generate significant revenues until and unless pelareorep becomes commercially viable;

•our estimations that we can fund operations into March 2026;

•our plans to fund ongoing operations by raising additional funds through the sale of our common shares or other capital resources, such as strategic collaborations and debt;

•the availability of additional liquidity and the terms thereof;

•the potential consequences of failing to secure adequate additional funding;

•our ability to reduce or eliminate planned expenditures to extend our operating runway if additional financing cannot be obtained when required;

•our plans to continue working with various collaborators, academics, and stakeholders on the most effective path forward for pelareorep;

•the focus of and plans for our manufacturing program and our belief that we have sufficient drug supply to support our clinical development program;

•our plans to protect and extend our intellectual property;

•our expectations regarding the timing and results of the Domestication (as defined below);

•our ongoing evaluation of all types of financing arrangements;

•our expectations regarding the sale of securities pursuant to the ATM sales agreement under the Form F-3 (as defined below) and the results thereof;

•our expectation that we will continue to access equity arrangements to help support our operations;

•our objective to maintain adequate cash reserves to support our planned activities, including our clinical trial program, product manufacturing, administrative costs and intellectual property protection and the methods used to achieve such objective;

•our continued management of our research and development plan, and potential changes to our contractual commitments and obligations that may result from changes to the plan;

•our expectation to fund our expenditure requirements and commitments with existing working capital;

•the judgment applied in assessing our ability to continue as a going concern and the material uncertainties that raise substantial doubt on our ability to continue as a going concern;

•our belief that we are not able to fund our operations for at least the next twelve months from the balance sheet date with the cash and cash equivalents on hand;

•the factors that affect our cash usage;

•our expectation that we will increase our spending in connection with the research and development of pelareorep over the next several years as we look to advance our programs to registration-enabled clinical studies and the increased costs associated with later stages of clinical development;

•our expectation that we will continue to incur additional costs associated with operating as a public company;

•the factors that may affect the probability of successful commercialization of pelareorep;

•our approach to credit, interest rate, foreign exchange, and liquidity risk mitigation, and our expectations with respect to the likelihood of these risks;

•the effectiveness of our internal control systems; and

•and other statements that are not historical facts or which are related to anticipated developments in our business and technologies.

In any forward-looking statement in which we express an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation, or belief will be achieved. Forward-looking statements involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements.

Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, our ability to successfully commercialize pelareorep, uncertainties related to the research, development, and manufacturing of pelareorep, uncertainties related to competition, changes in technology, the regulatory process, and general changes to the economic environment.

With respect to the forward-looking statements made within this MD&A, we have made numerous assumptions regarding, among other things: our ability to recruit and retain employees, our continued ability to obtain financing to fund our clinical development plan, our ability to receive regulatory approval to commence enrollment in the clinical studies which are part of our clinical development plan, our ability to maintain our supply of pelareorep, and future expense levels being within our current expectations.

Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Forward-looking statements are based on assumptions, projections, estimates, and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and/or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing undue reliance on forward-looking statements. We do not undertake any obligation to update these forward-looking statements except as required by applicable law.

We are a clinical-stage biopharmaceutical company developing pelareorep, a well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments.

Pelareorep is a proprietary isolate of reovirus, a naturally occurring, non-pathogenic double-stranded RNA (dsRNA) reovirus commonly found in environmental waters. Pelareorep has shown promising results in changing the tumor microenvironment (TME). This creates a more immunologically favorable TME, making the tumor more susceptible to various treatment combinations. These treatments include chemotherapies, checkpoint inhibitors, and other immuno-oncology approaches such as CAR T therapies, bispecific antibodies, and CDK4/6 inhibitors. Pelareorep induces a new army of tumor-reactive T cells, helps these cells to infiltrate the tumor through an inflammatory process, and upregulates the expression of PD-1/PD-L1. By priming the immune system with pelareorep, we believe we can increase the proportion of patients who respond to various cancer treatments, including immunotherapies, especially in cancers where existing treatment regimens have failed or provided limited benefit.

As our clinical development program advances, we anticipate pelareorep's ability to enhance innate and adaptive immune responses within the TME will play an increasingly important role. This greatly increases opportunities for expanding our clinical program, business development, and partnering opportunities to address a broad range of cancers in combination with various other therapies. We believe this approach has the most promise for generating clinically impactful data and offers the most expeditious path to regulatory approval.

Our primary focus is to position pelareorep as a platform immunotherapy for the treatment of gastrointestinal (GI) tumors and advance our GI program to registration-enabled clinical studies. We are exploring opportunities for registrational programs and investigator-sponsored trials in metastatic pancreatic cancer, second-line or later anal cancer, and metastatic colorectal cancer.

We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. As at September 30, 2025, we had cash and cash equivalents of $12,352. We estimate we can currently fund our operations into March 2026. We plan on raising additional funds through the sale of our common shares or other capital resources, such as strategic collaborations and debt, to fund our ongoing operations. However, given the difficulty for micro-cap market capitalization companies to raise significant capital, there can be no assurance that additional liquidity will be available under acceptable terms or at all. Furthermore, if we are unable to obtain additional financing when required, there can be no assurance that we will be able to sufficiently reduce or eliminate our planned expenditures to extend our operating runway. These material uncertainties raise substantial doubt on our ability to continue as a going concern. See further discussion in "Liquidity and Capital Resources".

The following are the development updates and outlook for each of our programs for the three months ended September 30, 2025, through to the date hereof:

In the third quarter of 2025, we announced that we are scheduled to meet with the U.S. Food and Drug Administration (FDA) in mid-November and provided an update on the proposed design of our planned registration-directed clinical trial in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). Key elements of the proposed registration study are as follows:

•Three-arm design – patients will be randomized to receive:

1.Gemcitabine + nab-paclitaxel (GnP) control arm.

2.GnP + pelareorep.

3.GnP + pelareorep + checkpoint inhibitor.

•Primary endpoint: Overall Survival.

•Statistical rigor: The trial will be powered to detect statistical significance between the investigational arms and the control arm.

•Planned interim analysis: An interim efficacy analysis will be incorporated to enable early assessment of potential clinical benefit.

In the third quarter of 2025, we announced the following updates on our GOBLET study:

In a randomized two-arm cohort, pelareorep is being evaluated in combination with modified FOLFIRINOX with or without atezolizumab to gain greater clarity regarding the contribution of the checkpoint inhibitor to the efficacy achieved in GOBLET Cohort 1. In that cohort, pelareorep combined with gemcitabine/nab-paclitaxel and atezolizumab achieved a 62% ORR in 13 evaluable patients. Enrollment into Cohort 5 is approximately 40% complete and is expected to be fully enrolled by the end of 2026. These activities were supported by the Pancreatic Cancer Action Network (PanCAN) Therapeutic Accelerator Award. We expect to provide a Cohort 5 interim efficacy update, including overall survival, in the first quarter of 2026.

We submitted a protocol amendment to allow the GOBLET study to open U.S. clinical sites starting in the fourth quarter of 2025. Upon approval, Northwestern University and other academic institutions are expected to serve as U.S. sites for GOBLET.

In October 2025, we reported updated efficacy data from Cohort 4 of the GOBLET study in second-line or later SCAC, which showed a 30% objective response rate (ORR), including two complete responses from 20 evaluable patients receiving pelareorep and atezolizumab. The ORR for the current standard of care therapy at this stage of treatment is 13.8%. The median duration of response for Cohort 4 patients is 15.5 months compared to 9.5 months for the current standard of care. We expect to discuss plans for a single-arm accelerated approval study with the FDA in the first quarter of 2026. Previous data presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in January 2025 from this cohort showed a 33% ORR, including one complete response from 12 evaluable patients.

In November 2025, we announced the formation of our Gastrointestinal (GI) Tumor Scientific Advisory Board (SAB), a group of leading oncology experts assembled to guide our clinical and regulatory strategy for developing pelareorep as a treatment for GI cancers. Inaugural members of the SAB include Sanjay Goel, M.D., M.S., FASCO, Professor of Medicine and Director of the Phase I Program at Rutgers Cancer Institute of New Jersey; Deva Mahalingam, M.D., Ph.D., Professor of Medicine, GI oncologist and Director of the Developmental Therapeutics Program, Lurie Cancer Center at Northwestern University; and Dirk Arnold, M.D., Ph.D., FESMO, Principal Investigator of the GOBLET study, Professor of Medicine, and Director of Asklepios Tumorzentrum Hamburg, Germany. These three members have been the lead investigators in clinical trials evaluating pelareorep-based treatment regimens spanning colorectal cancer, PDAC, and SCAC. The SAB is expected to expand to six total members who will bring additional industry-leading clinical and regulatory expertise in these high-need GI cancer indications.

We are actively evaluating multiple strategic partnership options to advance the development of pelareorep. We expect to obtain regulatory clarity on a registration-enabled study for first-line mPDAC by the end of 2025. In parallel, we continue to engage with collaborators, academic partners, and other stakeholders to determine the most effective path forward for pelareorep.

While we currently have sufficient drug product supply to support our clinical development program, including for a registration-enabled study in mPDAC, we continued our activities to expand our production capabilities as we focus on advancing our active drug substance and finished drug product toward registration and commercial readiness. During the third quarter of 2025, we substantially completed a cGMP production run and a cGMP drug product fill with a secondary fill/finish supplier. We also incurred storage and distribution costs to maintain our product supply. Ongoing bulk manufacturing and expanded filling capabilities are both part of the planned process validation. Continued process validation is required to ensure that the resulting product meets the specifications and quality standards and will form part of our submission to regulators, including the FDA, for product approval.

For the remainder of 2025, our manufacturing program will focus on completing a formal assessment of the drug substance production process in preparation for performance qualification, completing the potency assay validation, and supply distribution for our ongoing and planned studies.

At the end of the third quarter of 2025, we had 149 patents, including 11 U.S. and 8 Canadian patents, and issuances in other jurisdictions. We have an extensive patent portfolio covering pelareorep and formulations that we use in our clinical trial program. We also have patents covering methods for manufacturing pelareorep and screening for susceptibility to pelareorep. These patent rights extend to at least the end of 2031. We are continuing to analyze additional patent protections and have placed an emphasis on patent extension strategy. In addition, we have made patent applications that we expect to extend certain patent protection and grant new rights into the 2040s.

During the three months ended September 30, 2025, we sold 3,872,394 common shares for gross proceeds of $4,433 (US$3,242) at an average price of $1.14 (US$0.84). We received proceeds of $4,300 (US$3,145) after commissions of $133 (US$97). In total, we incurred share issue costs (including commissions) of $194.

On October 17, 2025, we entered into an ATM sales agreement with BTIG, LLC (BTIG). The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$50,000 through the facilities of the Nasdaq in the United States.

We ended the third quarter of 2025 with cash and cash equivalents of $12,352 (see "Liquidity and Capital Resources").

On October 20, 2025, we filed a registration statement on Form F-4 with the U.S. Securities and Exchange Commission that included a preliminary management circular/prospectus and other relevant documents related to various proposals contained therein. It included plans to hold a Special Meeting of Shareholders to vote on, among other things, a series of transactions that will change the jurisdiction of Oncolytics from the Province of Alberta in Canada to the State of Nevada in the United States of America (the "Domestication"). If approved, the Domestication is expected to occur in early 2026, or as soon as practicable thereafter. There are not expected to be any material changes to the Company’s operations or financial results as a result of the Domestication. The ongoing U.S. federal government shutdown may delay the Special Meeting of Shareholders and the implementation of the Domestication.

Unless otherwise indicated, all amounts below are presented in thousands of Canadian dollars, except for share amounts.

Net loss for the three months ended September 30, 2025, was $14,400 compared to $9,543 for the three months ended September 30, 2024.

Our R&D expenses increased by $721 from $6,794 for the three months ended September 30, 2024, to $7,515 for the three months ended September 30, 2025. The following table summarizes our R&D expenses for the three months ended September 30, 2025, and 2024:

R&D expenses increased in the third quarter of 2025, primarily due to the following:

•Increased manufacturing and related process development expenses as we substantially completed a cGMP production run and drug product fill;

•Increased intellectual property expenses related to executing our patent extension strategy and new patent applications; and

•Increased personnel-related expenses associated with the vesting of inducement awards granted to our new Chief Executive Officer in the second quarter of 2025 and options granted in the third quarter of 2025.

The above increases were partially offset by lower clinical trial expenses largely driven by lower BRACELET-1 study costs as the study was completed in 2024. In the third quarter of 2025, we focused our R&D efforts on patient enrollment and sample analysis for Cohort 5 of the GOBLET study. These activities were supported by the PanCAN Therapeutic Accelerator Award, of which $586 of the funds received were applied.

Our G&A expenses increased by $3,220 from $3,105 for the three months ended September 30, 2024, to $6,325 for the three months ended September 30, 2025. The following table summarizes our G&A expenses for the three months ended September 30, 2025, and 2024:

G&A expenses increased in the third quarter of 2025, primarily due to increased public company-related expenses associated with higher investor relations activities and professional fees related to our Domestication activities, voluntary delisting from the Toronto Stock Exchange (TSX), and the upcoming Special Meeting of Shareholders. Our public company-related expenses for the three months ended September 30, 2025 included $2,323 of non-cash share-based compensation expense for consulting services.

In the third quarter of 2025, we recognized losses of $1,052 on the change in fair value of our warrant derivative compared to gains of $229 in the third quarter of 2024. There was no cash flow impact as a result of the change in fair value of the warrant derivative. In the third quarter of 2025, the underlying market price of these warrants changed from US$0.76 at June 30, 2025, to US$1.40 at September 30, 2025. In the third quarter of 2024, the underlying market price of these warrants changed from US$0.99 at June 30, 2024, to US$0.88 at September 30, 2024. The number of outstanding warrants was 7,667,050 at September 30, 2025, and June 30, 2025.

Our foreign exchange gains were $140 for the third quarter of 2025 compared to losses of $122 for the third quarter of 2024. The foreign exchange impact mainly reflected the fluctuation of the U.S. dollar versus the Canadian dollar throughout the respective periods, primarily on our U.S. dollar-denominated cash and cash equivalents.

Net loss for the nine months ended September 30, 2025, was $27,252 compared to $23,693 for the nine months ended September 30, 2024.

Our R&D expenses decreased by $2,688 from $17,095 for the nine months ended September 30, 2024, to $14,407 for the nine months ended September 30, 2025. The following table summarizes our R&D expenses for the nine months ended September 30, 2025, and 2024:

R&D expenses decreased for the nine months ended September 30, 2025, primarily due to the following:

•Decreased clinical trial expenses mainly due to lower BRACELET-1 study costs as the study was completed in 2024. We also incurred lower planning-related expenses compared to the same period in the prior year. During the nine months ended September 30, 2025, we focused our R&D efforts on patient enrollment and sample analysis for Cohort 5 of the GOBLET study. These activities were supported by the PanCAN Therapeutic Accelerator Award, of which $2,249 of the funds received were applied; and

•Decreased manufacturing and related process development expenses as we substantially completed a cGMP production run compared to two cGMP production runs executed during the same period in the prior year. We also initiated potency assay validation using our master cell bank and completed production of a new working cell bank during the same period in the prior year.

The above decreases were partially offset by the following:

•Increased intellectual property expenses related to executing our patent extension strategy and new patent applications; and

•Increased personnel-related expenses associated with CEO transition activities.

Our G&A expenses increased by $2,688 from $9,450 for the nine months ended September 30, 2024, to $12,138 for the nine months ended September 30, 2025. The following table summarizes our G&A expenses for the nine months ended September 30, 2025, and 2024:

G&A expenses increased for the nine months ended September 30, 2025, primarily due to increased public company-related expenses as a result of higher investor relations activities and professional fees related to our Domestication activities, voluntary delisting from the TSX, and the upcoming Special Meeting of Shareholders. These expenses were partially offset by lower directors and officers insurance premiums. Our public company-related expenses for the nine months ended September 30, 2025, included $2,323 of non-cash share-based compensation expense for consulting services.

For the nine months ended September 30, 2025, we recognized losses of $1,008 on the change in fair value of our warrant derivative compared to gains of $1,333 for the nine months ended September 30, 2024. There was no cash flow impact as a result of the change in fair value of the warrant derivative. For the nine months ended September 30, 2025, the underlying market price of these warrants changed from US$0.92 at December 31, 2024, to US$1.40 at September 30, 2025. For the nine months ended September 30, 2024, the underlying market price of these warrants changed from US$1.35 at December 31, 2023, to US$0.88 at September 30, 2024. The number of outstanding warrants was 7,667,050 at September 30, 2025, and December 31, 2024.

Our foreign exchange losses for the nine months ended September 30, 2025, were $193 compared to gains of $579 for the nine months ended September 30, 2024. The foreign exchange impact mainly reflected the fluctuation of the U.S. dollar versus the Canadian dollar throughout the respective periods, primarily on our U.S. dollar-denominated cash and cash equivalents.

Historical patterns of expenditures cannot be taken as an indication of future expenditures. Our current and future expenditures are subject to numerous uncertainties, including the duration, timing, and costs of R&D activities ongoing during each period and the availability of funding from investors and prospective partners. As a result, the amount and timing of expenditures and, therefore, liquidity and capital resources may vary substantially from period to period.

(1)Included in consolidated net loss and loss per common share were share-based compensation expenses of $4,118, $523, $1,208, $1,196, $445, $506, $576, and $759, respectively.

(2)Included in consolidated net loss and loss per common share were foreign exchange gains (losses) of $140, $(282), $(51), $382, $(122), $184, $517, and $(392), respectively.

(3)Included in consolidated net loss and loss per common share were (losses) gains resulting from a change in fair value of warrant derivative of $(1,052), $(196), $240, $(91), $229, $235, $869, and $4,846, respectively.

(4)We raised net cash proceeds of $4,239, $5,475, $5,993, $3,439, nil, $2,040, $1,598, and $1,846, respectively, from issuing common shares.

(5)We have not declared or paid any dividends since incorporation.

During the quarter ended September 30, 2024, we completed a cGMP production run, resulting in higher manufacturing and related process development expenses. During the quarters ended December 31, 2024, and 2023, we incurred expenses related to annual short-term incentive awards. During the quarter ended September 30, 2025, we incurred higher public company-related expenses associated with higher investor relations activities and professional fees related to our upcoming special meeting of shareholders. We also completed a cGMP production run, resulting in higher manufacturing and related process development expenses.

As a clinical-stage biopharmaceutical company, we have not been profitable since our inception. We expect to continue to incur substantial losses as we continue our research and development efforts. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. See "Operating Capital Requirements" below for the discussion on our ability to continue as a going concern. To date, we have funded our operations mainly through issuing additional capital via public offerings, equity distribution arrangements, and the exercise of warrants and stock options. For the nine months ended September 30, 2025, we raised funds through our U.S. ATM and share purchase agreement.

We have no assurances that we will be able to raise additional funds through the sale of our common shares. Consequently, we will continue to evaluate all types of financing arrangements, such as strategic collaborations and debt, to fund our ongoing operations.

The F-3 provides additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in the Company. Funds received from using our Form F-3 would be used in line with our Board-approved budget and multi-year plan.

Our Form F-3 allowed us to enter into our ATM sales agreement with BTIG. We plan to use this equity arrangement to assist us in achieving our capital objective. This arrangement provides us with the opportunity to raise capital and better manage our cash resources. We expect to access this equity arrangement to help support our operations.

As at September 30, 2025, and December 31, 2024, we had cash and cash equivalents as follows:

We have no debt other than accounts payable and accrued liabilities and lease liabilities. We have commitments relating to completing our research and development of pelareorep.

The following table summarizes our cash flows for the periods indicated:

The decrease reflected lower net operating activities and non-cash working capital changes in 2025.

Cash used in operating activities for the nine months ended September 30, 2025, consisted of a net loss of $27,252 offset by non-cash adjustments of $7,114 and non-cash working capital changes of $1,518. Non-cash items primarily included share-based compensation expense and change in fair value of warrant derivative. Non-cash working capital changes mainly reflected increased accounts payable and accrued liabilities and decreased other liabilities (see note 13 of our condensed interim consolidated financial statements).

Cash used in operating activities for the nine months ended September 30, 2024, consisted of a net loss of $23,693 offset by non-cash adjustments of $75 and by non-cash working capital changes of $4,498. Non-cash items primarily included change in fair value of warrant derivative, share-based compensation expense, and unrealized foreign exchange gains. Non-cash working capital changes mainly reflected increased accounts payable and accrued liabilities and decreased prepaid expenses (see note 13 of our condensed interim consolidated financial statements).

During the nine months ended September 30, 2025, we sold, through our ATM, 12,441,368 common shares for gross proceeds of $13,147 (US$9,392) at an average price of $1.06 (US$0.75). We also sold 6,650,000 common shares for gross proceeds of $3,233 (US$2,348) at an average price of $0.49 (US$0.35) through our share purchase agreement. During the nine months ended September 30, 2024, we sold 2,596,533 common shares for gross proceeds of $4,062 (US$2,998) at an average price of $1.56 (US$1.15).

Our objective is to maintain adequate cash reserves to support our planned activities, including our clinical trial program, product manufacturing, administrative costs, and intellectual property protection. To do so, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the associated costs. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year’s activity. Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board. We continue to manage our research and development plan to ensure optimal use of our existing resources as we expect to fund our expenditure requirements and commitments with existing working capital.

Management assesses our ability to continue as a going concern. In our going concern assessment, management takes into account all available information about the future, which is at least, but not limited to, twelve months from the end of the reporting period. We have concluded that our cash and cash equivalents are not sufficient to fund our planned operations and meet our obligations for the twelve months following the balance sheet date without raising additional funding or reducing or eliminating our planned expenditures. Factors that will affect our anticipated cash usage for which additional funding might be required include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of R&D activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken, and other factors described in the "Risk Factors" section of our most recent annual report on Form 20-F. The judgment and assumptions applied by management may prove to be wrong, and actual results could vary materially from our expectations as significant risks and uncertainties are involved.

We expect to increase our spending in connection with the research and development of pelareorep over the next several years as we look to position pelareorep as a platform immunotherapy for the treatment of GI tumors and advance our GI program to registration-enabled clinical studies.

A product candidate in later stages of clinical development generally has higher costs than those in earlier stages, primarily due to the increased size and duration of later-stage clinical trials. Additionally, we expect to continue to incur additional costs associated with operating as a public company.

We plan on raising additional funds through the sale of our common shares or other capital resources, such as strategic collaborations and debt, to fund our ongoing operations. However, given the difficulty for micro-cap market capitalization companies to raise significant capital, there can be no assurance that additional liquidity will be available under acceptable terms or at all. Furthermore, if we are unable to obtain additional financing when required, there can be no assurance that we will be able to sufficiently reduce or eliminate our planned expenditures to extend our operating runway until we obtain sufficient financing. These material uncertainties raise substantial doubt on our ability to continue as a going concern. Our condensed interim consolidated financial statements do not reflect the adjustments that may result from the outcome of these uncertainties. Such adjustments could be material.

To the extent that we can raise additional funds by issuing equity, our shareholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that may impact our ability to conduct our business. If we are unable to secure adequate additional funding, we may be forced to make reductions in spending, including potentially delaying, scaling back or eliminating certain of our development programs, extending payment terms with suppliers, or liquidating assets where possible. Any of these actions could materially harm our business, results of operations and future prospects.

Conducting clinical trials necessary to obtain regulatory approval is costly and time-consuming. We may never succeed in achieving marketing approval. The probability of successful commercialization of our drug candidates may be affected by numerous factors, including clinical data obtained in future trials, competition, manufacturing capability and commercial viability. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates.

The following table summarizes our significant contractual obligations as at September 30, 2025:

In addition, we are committed to payments totaling approximately $3,200 for activities mainly related to our clinical trial and manufacturing programs, which are expected to occur over the next two years. We are able to cancel most of these agreements with notice. The ultimate amount and timing of these payments are subject to changes in our research and development plan.

As at September 30, 2025, we had not entered into any off-balance sheet arrangements.

During the three and nine months ended September 30, 2025, and 2024, we did not enter into any related party transactions other than compensation paid to key management personnel. Key management personnel are those persons having authority and responsibility for planning, directing, and controlling our activities as a whole. We have determined that key management personnel comprise the Board of Directors, Executive Officers, President, and Vice Presidents.

In preparing our condensed interim consolidated financial statements, we use IFRS as issued by the IASB. IFRS requires us to make certain estimates, judgments, and assumptions that we believe are reasonable based on the information available in applying our accounting policies. These estimates and assumptions affect the reported amounts and disclosures in our condensed interim consolidated financial statements and accompanying notes. Actual results could differ from those estimates, and such differences could be material.

Our critical accounting policies and estimates are described in our audited consolidated financial statements for the year ended December 31, 2024, and available on SEDAR+ at www.sedarplus.ca and contained in our annual report on Form 20-F filed on EDGAR at www.sec.gov/edgar.

There were no material changes to our critical accounting policies in the nine months ended September 30, 2025.

In April 2024, the IASB issued IFRS 18 Presentation and Disclosure in Financial Statements which replaces IAS 1 Presentation of Financial Statements. IFRS 18 introduces new requirements on presentation within the statement of profit or loss, including specified totals and subtotals. It also requires disclosure of management-defined performance measures and includes new requirements for aggregation and disaggregation of financial information based on the identified roles of the primary financial statements and the notes. Narrow scope amendments have been made to IAS 7 Statement of Cash Flows and some requirements previously included within IAS 1 have been moved to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors, which has also been renamed IAS 8 Basis of Preparation of Financial Statements. IAS 34 Interim Financial Reporting has also been amended to require disclosure of management-defined performance measures. IFRS 18 and the amendments to the other standards are effective for annual periods beginning on or after January 1, 2027, with early application permitted. IFRS 18 applies retrospectively to both annual and interim financial statements. We do not expect this amendment to materially impact our consolidated financial statements.

Effective January 1, 2026, we will become a domestic issuer under the rules of the U.S. Securities and Exchange Commission, and will no longer qualify as a "foreign private issuer" under those rules. As a result, we will have to prepare our December 31, 2025 annual financial statements in accordance with US GAAP, with such changes being applied retrospectively. The extent of the impact of the adoption of US GAAP has not yet been fully determined.

As at September 30, 2025, and December 31, 2024, the carrying amount of our cash and cash equivalents, other receivables, accounts payable and accrued liabilities, and other liabilities approximated their fair value due to their short-term maturity. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and, therefore, do not trade on an active market. As at September 30, 2025, the fair value of our warrant derivative was $29 (December 31, 2024 - presented as an asset of $980). The change was mainly due to the revaluation of our warrants issued as part of our 2023 public offering. An initial discount was recognized as the difference between the fair value of the warrants and their allocated proceeds, which is amortized on a straight-line basis over the expected life of the warrants (see note 6 of our condensed interim consolidated financial statements). We use the Black-Scholes valuation model to estimate fair value.

Credit risk is the risk of a financial loss if a counterparty to a financial instrument fails to meet its contractual obligations. As at September 30, 2025, we were exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents.

Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. For the nine months ended September 30, 2025, we were primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar and Euro, as a portion of our financial assets and liabilities were denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have increased our comprehensive loss in 2025 by approximately $89 (September 30, 2024 - decrease of $29). The impact of a $0.01 increase in the value of the Euro against the Canadian dollar would have increased our comprehensive loss in 2025 by approximately $36 (September 30, 2024 - $25).

Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. We manage liquidity risk through the management of our capital structure as outlined in note 11 to our condensed interim consolidated financial statements. Accounts payable and accrued liabilities are all due within the current operating period. Other liabilities associated with funding received from PanCAN (see note 4 in our condensed interim consolidated financial statements) are expected to be applied within the current operating period. See note 5 in our condensed interim consolidated financial statements for a maturity analysis of our lease liabilities.

The following table provides an update on the anticipated use of proceeds raised as part of the 2023 public offering of common shares and warrants along with amounts actually expended. As at September 30, 2025, the following expenditures have been incurred (in thousands of U.S. dollars):

Item			Amount to Spend						Spent to Date						Adjustments						Remaining to Spend
Pancreatic Cancer Program			$	10,500					$	(9,972)					$	(528)					$	—
Breast Cancer Program			500						(1,028)						528						—
General and Administrative Expenses			2,650						(2,650)						—						—
Total			$	13,650					$	(13,650)					$	—					$	—

We have 106,146,382 common shares outstanding at November 12, 2025. If all of our stock options and share awards (20,040,483) and common share purchase warrants (8,203,743) were exercised, we would have 134,390,608 common shares outstanding.

Our 2024 annual report on Form 20-F is available on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov/edgar.

Disclosure controls and procedures (“DC&P”) are designed to provide reasonable assurance that information required to be disclosed by the Company in its reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in the securities legislation and include controls and procedures designed to ensure that information required to be disclosed by the Company in its reports filed or submitted under securities legislation is accumulated and communicated to the Company’s management, including its certifying officers, as appropriate to allow timely decisions regarding required disclosure. There were no changes in our DC&P during the three months ended September 30, 2025, that materially affected or are reasonably likely to materially affect, our DC&P.

The Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") are responsible for designing internal controls over financial reporting (“ICFR”) or causing them to be designed under their supervision in order to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS. The CEO and CFO have designed, or caused to be designed under their supervision, ICFR to provide reasonable assurance that: (i) material information relating to the Company is made known to the Company's CEO and CFO by others; and (ii) information required to be disclosed by the Company in its reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time period specified in securities legislation. The Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) 2013 framework provides the basis for management’s design of internal controls over financial reporting. There were no changes in our ICFR during the three months ended September 30, 2025, that materially affected or are reasonably likely to materially affect, our ICFR.

Management, including the CEO and CFO, does not expect that our internal controls and procedures over financial reporting will prevent all errors and all fraud. A control system can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future conditions. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

We are a clinical-stage biopharmaceutical company. Prospects for biotechnology companies in the research and development stage should generally be regarded as speculative. It is not possible to predict, based on studies in animals, or early studies in humans, whether a new therapeutic will ultimately prove to be safe and effective in humans or whether necessary and sufficient data can be developed through the clinical trial process to support a successful product application and approval. If a product is approved for sale, product manufacturing at a commercial scale and significant sales to end users at a commercially reasonable price may not be successful. There can be no assurance that we will generate adequate funds to continue development or will ever achieve significant revenues or profitable operations. Many factors (e.g., competition, patent protection, appropriate regulatory approvals) can influence the revenue and product profitability potential. In developing a pharmaceutical product, we rely on our employees, contractors, consultants and collaborators, and other third-party relationships, including the ability to obtain appropriate product liability insurance. There can be no assurance that this reliance and these relationships will continue as required. In addition to developmental and operational considerations, market prices for securities of biotechnology companies generally are volatile, and may or may not move in a manner consistent with the progress we have made or are making.

Investment in our common shares involves a high degree of risk. An investor should carefully consider, among other matters, the risk factors in addition to the other information in our annual report on Form 20-F filed with the U.S. Securities and Exchange Commission (the "SEC"), as well as our other public filings with the Canadian securities regulatory authorities and the SEC, when evaluating our business because these risk factors may have a significant impact on our business, financial condition, operating results or cash flow. If any of the described material risks in our annual report or in subsequent reports we file with the regulatory authorities actually occur, they may materially harm our business, financial condition, operating results or cash flow. Additional risks and uncertainties that we have not yet identified or that we presently consider to be immaterial may also materially harm our business, financial condition, operating results, or cash flow. For information on risks and uncertainties, please refer to the "Risk Factors" section of our most recent annual report on Form 20-F and our other public filings available on www.sedarplus.ca and www.sec.gov/edgar.

I, Jared Kelly, CEO of Oncolytics Biotech Inc., certify the following:

1.Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Oncolytics Biotech Inc. (the “issuer”) for the interim period ended September 30, 2025.

2.    No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

3.    Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

4.    Responsibility: The issuer’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52‑109 Certification of Disclosure in Issuers’ Annual and Interim Filings, for the issuer.

5.    Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer(s) and I have, as at the end of the period covered by the interim filings:

(a)    designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that:

(i)    material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

(ii)    information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

(b)    designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.

5.1    Control framework: The control framework the issuer’s other certifying officer and I used to design the issuer’s ICFR is the Internal Control -- Integrated Framework (2013) published by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).

5.2    ICFR ‑ material weakness relating to design: N/A.

5.3    Limitation on scope of design: N/A.

6.    Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer’s ICFR that occurred during the period beginning on July 1, 2025 and ended on September 30, 2025 that has materially affected, or is reasonably likely to materially affect, the issuer’s ICFR.

I, Kirk Look, CFO of Oncolytics Biotech Inc., certify the following:

1.    Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Oncolytics Biotech Inc. (the “issuer”) for the interim period ended September 30, 2025.

2.    No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

3.    Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

4.    Responsibility: The issuer’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52‑109 Certification of Disclosure in Issuers’ Annual and Interim Filings, for the issuer.

5.    Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer(s) and I have, as at the end of the period covered by the interim filings:

(a)    designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that:

(i)    material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

(ii)    information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

(b)    designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.

5.1    Control framework: The control framework the issuer’s other certifying officer and I used to design the issuer’s ICFR is the Internal Control -- Integrated Framework (2013) published by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).

5.2    ICFR ‑ material weakness relating to design: N/A.

5.3    Limitation on scope of design: N/A.

6.    Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer’s ICFR that occurred during the period beginning on July 1, 2025 and ended on September 30, 2025 that has materially affected, or is reasonably likely to materially affect, the issuer’s ICFR.